Calamos Advisors LLC Sells 70,827 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Calamos Advisors LLC lowered its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 68.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,021 shares of the medical equipment provider's stock after selling 70,827 shares during the period. Calamos Advisors LLC owned approximately 0.07% of BioLife Solutions worth $857,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Stifel Financial Corp increased its position in shares of BioLife Solutions by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock worth $325,000 after purchasing an additional 670 shares during the last quarter. GAMMA Investing LLC lifted its holdings in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after buying an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of BioLife Solutions by 5.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider's stock worth $296,000 after acquiring an additional 753 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter valued at about $28,000. Finally, Curi RMB Capital LLC increased its position in BioLife Solutions by 0.5% in the third quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider's stock worth $10,565,000 after buying an additional 2,283 shares during the period. 93.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on BLFS shares. Benchmark reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. Northland Securities boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. HC Wainwright decreased their price objective on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. Finally, TD Cowen lifted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $29.43.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the business's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares of the company's stock, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Aby J. Mathew sold 17,604 shares of the company's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $20.05, for a total transaction of $352,960.20. Following the transaction, the executive vice president now owns 284,442 shares in the company, valued at approximately $5,703,062.10. This trade represents a 5.83 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,278 shares of company stock valued at $1,199,987. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Stock Performance

Shares of BLFS stock traded down $0.09 during mid-day trading on Friday, reaching $26.10. The company's stock had a trading volume of 297,726 shares, compared to its average volume of 218,552. The firm's 50-day moving average is $26.76 and its two-hundred day moving average is $25.21. BioLife Solutions, Inc. has a 1-year low of $14.50 and a 1-year high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.